JP2024538730A - がん及び腫瘍を治療するための方法 - Google Patents

がん及び腫瘍を治療するための方法 Download PDF

Info

Publication number
JP2024538730A
JP2024538730A JP2024521109A JP2024521109A JP2024538730A JP 2024538730 A JP2024538730 A JP 2024538730A JP 2024521109 A JP2024521109 A JP 2024521109A JP 2024521109 A JP2024521109 A JP 2024521109A JP 2024538730 A JP2024538730 A JP 2024538730A
Authority
JP
Japan
Prior art keywords
substituted
cancer
compound
formula
methylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538730A5 (https=
Inventor
ケネス ロイド，ジョージ
モハンラル，ラモーン
アール． トンラ，ジェームス
ファン，ラン
Original Assignee
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド filed Critical ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Publication of JP2024538730A publication Critical patent/JP2024538730A/ja
Publication of JP2024538730A5 publication Critical patent/JP2024538730A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024521109A 2021-10-07 2022-10-06 がん及び腫瘍を治療するための方法 Pending JP2024538730A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253332P 2021-10-07 2021-10-07
US63/253,332 2021-10-07
PCT/US2022/077702 WO2023060200A1 (en) 2021-10-07 2022-10-06 Methods for treating cancers and tumors

Publications (2)

Publication Number Publication Date
JP2024538730A true JP2024538730A (ja) 2024-10-23
JP2024538730A5 JP2024538730A5 (https=) 2025-10-15

Family

ID=85804784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521109A Pending JP2024538730A (ja) 2021-10-07 2022-10-06 がん及び腫瘍を治療するための方法

Country Status (6)

Country Link
US (1) US20240408082A1 (https=)
EP (1) EP4412613A4 (https=)
JP (1) JP2024538730A (https=)
CN (1) CN118369101A (https=)
CA (1) CA3234699A1 (https=)
WO (1) WO2023060200A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005212399B2 (en) * 2004-02-04 2011-09-22 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
AU2016229294B2 (en) * 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
MX2021001762A (es) * 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.
JP2022513038A (ja) * 2018-11-14 2022-02-07 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合薬を使用する癌の治療方法

Also Published As

Publication number Publication date
WO2023060200A1 (en) 2023-04-13
CA3234699A1 (en) 2023-04-13
EP4412613A4 (en) 2025-10-22
US20240408082A1 (en) 2024-12-12
CN118369101A (zh) 2024-07-19
EP4412613A1 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
JP2024538730A (ja) がん及び腫瘍を治療するための方法
JP7405881B2 (ja) 好中球減少症を低減させるための組成物および方法
US8802702B2 (en) Compounds for reducing drug resistance and uses thereof
JP6754071B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
AU2002210993B2 (en) Medicinal compositions for concominant use as anticancer agents
US20190225609A1 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
US12257237B2 (en) Tinostamustine for use in treating sarcoma
US7951780B2 (en) Antitumor agent
US6921772B2 (en) Methods and compositions for the treatment of chronic lymphocytic leukemia
US8372830B2 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
US10639304B2 (en) Kinase inhibitors
CN112166111A (zh) 治疗纤维化疾病的方法
KR20160106042A (ko) 암 치료용 약학적 배합물
US6632832B1 (en) Anti-cancer activity of carvedilol and its isomers
TW201912153A (zh) 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
JP7393808B2 (ja) 皮膚障害の処置のためのナフチリジノン－アニリン化合物
US20160339001A1 (en) Novel Methods for Treating Cancer
CN114599371A (zh) 作为癌症靶向药物载体的磷脂醚缀合物
KR20070026646A (ko) 프롤린 또는 이의 유도체 및 항종양 항체를 함유하는 항암조성물
US20190231793A1 (en) Use of harringtonines in the treatment of breast cancer, in particular triple-negative breast cancer
US7323481B2 (en) Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
US6812251B2 (en) Taurine compounds
US20240051969A1 (en) Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer
HK40109587A (zh) 治疗癌症和肿瘤的方法
US20070009531A1 (en) Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251006